This CPB is revised to state that vestronidase alfa-vjbk (Mepsevii) is considered medically necessary for children and adults 5 months to 25 years of age who meet the following criteria: 1) confirmed diagnosis of mucopolysaccharidosis type VII (MPS 7) based on leukocyte or fibroblast glucuronidase enzyme assay or genetic test; and 2) elevated urinary glycosaminoglycan (uGAG) excretion at a minimum of 2-fold over the mean normal for age at initiation.